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1741Era of Change in Sites of
Service for Peripheral
Vascular Intervention
Requires New Ways to
Look at CostsTABLE 1 Medicare Outpatient Payments for Peripheral Atherectomy
(2007-2011)
Fiscal year 2007 2008 2009 2010 2011
APC Number* 81 82 82 82 229
Payment amount $2,639 $5,574 $5,962 $6,275 $8,025
Medicare Outpatient Payments for Peripheral Stent Placement
(2007-2011)
APC Number 229 229 229 229 2011
Payment Amount $4,209 $5,639 $6,094 $6,541 $8,025
*APC is the ambulatory payment classiﬁcation, the payment system by which Medicare reimburses
outpatient hospitals.I read with interest the article by Jones et al. (1) in the
March 10, 2015, issue of the Journal. I am concerned
that, based on the methodology and data presented,
the conclusions may be misleading and suggest that
interventionalists are making treatment decisions for
peripheral vascular interventions (PVIs) and the
choice of atherectomy, particularly, based on ﬁnancial
remuneration rather than on scientiﬁc evidence,
depth of clinical experience, and interest in improving
outcomes for patients.
The article presented data for Medicare fee-for-
service beneﬁciaries between 2006 and 2011,
showing no statistical increase in overall rate of PVIs,
but with signiﬁcant shifts in site of services from
inpatient hospitalization to outpatient and ofﬁce
settings. Additionally, increases in atherectomy pro-
cedures during that time period were presented
as two-fold in the hospital outpatient setting and
50-fold in the ofﬁce setting. The authors concluded
that changes in reimbursement intended to result in
cost savings to Medicare inadvertently drove the shift
in PVI site of service and the increase in atherectomy
procedures in outpatient and ofﬁce settings, thereby
neutralizing cost savings. However, several points of
clariﬁcation are necessary for accurate interpretation
of the presented data.
First, the article presents an increase in atherectomy
procedures up to 50-fold in the ofﬁce setting during the
study period. However, unlike percutaneous trans-
luminal angioplasty (PTA) and stenting, atherectomy
was essentially nonexistent in the ofﬁce setting until
2011, when it ﬁrst became eligible for reimbursement
for similar Medicare beneﬁciaries as the study popu-
lation. Ignoring this development and reporting a
trend over the entire time period of 2006 to 2011 is
misleading. Moreover, Table 1 shows that from 2006 to
2011, the majority of atherectomies (95.7%) were per-
formed in the hospital setting versus the ofﬁce (4.2%).
By comparing absolute numbers of atherectomy pro-
cedures in the ofﬁce setting in 2010 (n ¼ w0 pro-
cedures) versus 2011 (n ¼ 292 procedures) (see Table 3
in Jones et al. [1]), this relatively small absolute in-
crease becomes overmagniﬁed when quantiﬁed as a
percentage. Atherectomies performed in the ofﬁce in2011 represented only 16% of the total number of
atherectomies performed for that year in all 3 settings.
Second, mean costs of atherectomy procedures are
presented as exceeding those of stenting and PTA
procedures during the study period. However, in the
hospital outpatient setting, atherectomy was reim-
bursed at the same level as PTA until 2008, and less
than or equal to stent procedures since 2008 (Table 1).
In addition, the utilization and costs of atherectomy
are likely overestimated relative to those of stenting
as the PVIs in the article were categorized as angio-
plasty, stenting, or atherectomy, without regard to
procedures involving more than one treatment mo-
dality, and the costs of procedures using both ather-
ectomy and stenting were only attributed to
atherectomy in the analysis.
Third, the analysis excluded patients undergoing
expensive surgical or hybrid revascularization pro-
cedures (n ¼ 8,901 [20.6%]) from the entire pool of
39,339 patients who underwent revascularization.
Therefore, the conclusion about the erosion of sav-
ings due to shift in site of service and outpatient re-
imbursements is based on incomplete information
that ignores the substantial reduction in the rate of
surgical bypass procedures (33%; p < 0.001) during
the study period. Considering that lower extremity
bypass surgery is an expensive, inpatient-only pro-
cedure typically requiring a 3.8- to 10-day length of
stay (LOS) and with Medicare costs ranging from
$17,215 to $28,983 per bypass procedure (FY 2011
rates), the signiﬁcant reduction in surgical pro-
cedures which likely resulted in signiﬁcant cost sav-
ings to Medicare is not represented fairly in this
analysis. (Medical provider analysis and review data
for ﬁscal years [FY] 2009–2012, and FYs 2011–2014
Final Rules also are available at the Centers for Medi-
care and Medicaid Services website.)
Fourth, the patients treated with atherectomy in
the study represented a sicker population than those
who received stents. Atherectomy patients were more
likely to be older black males (p < 0.002) with
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disease, heart failure, and stroke, compared to pa-
tients who underwent stenting (p < 0.001). These
comorbidities are associated with critical limb
ischemia (CLI) and amputation as well as longer,
complex, and more heavily calciﬁed lesions in the
infrapopliteal arteries, which may result in less effec-
tive treatment with balloons and stents alone (2). The
differences in patient populations could also indicate
an improved access to care (i.e., patients were treated
who would otherwise have been treated surgically or
who would not have undergone revascularization at
all). These clinical considerations in treatment choices
were not addressed in the authors’ conclusions, nor
did the authors assess the patient outcomes.
Fifth, the authors cited lack of efﬁcacy and
comparative evidence to justify the increased use of
atherectomy. However, during the study period,
paucity of data was true for the entire ﬁeld of pe-
ripheral artery disease (PAD) treatment. Often, prac-
tice patterns change in advance of published data,
based on clinical experience to support therapeutic
decision making. In the last several years, numerous
clinical device trials in PAD patients have reached
completion, and evidence has been published. In the
Zilver PTX trial, data clearly demonstrate that PTA
alone in the femoropopliteal artery segment is not a
satisfactory procedure due to high restenosis rates,
resulting in a poor 12-month primary patency rate as
low as 32.8%. Similar poor results were seen in the
clinically driven target lesion revascularization (TLR)
rate at 12 months post-PTA of 17.5% (3). Although
some bare-metal and drug-eluting stents have
improved patency and TLR rates signiﬁcantly (3),
concerns remain regarding the high cost of treating
in-stent restenosis (ISR).
Atherectomy (plaque removal) is a therapeutic mo-
dality that preserves the native vessel for future
treatment options without leaving a permanent
implant (metal stent) behind. In addition, atherectomy
reduces the need for costly revision of in-stent reste-
nosis, avoids or reduces the amount of barotrauma to
the vessel, and has a lower dissection rate than PTA,
while reducing the rates of target lesion revasculari-
zation. One of the largest, prospective, multicenter
studies, the DEFINITIVE LE study (Determination of
EFfectiveness of the SilverHawk PerIpheral Plaque
ExcisioN System [SIlverHawk Device] for the Treat-
ment of Infrainguinal VEssels/Lower Extremities),
included 800 patients and conﬁrmed the fact that
directional atherectomy is safe and effective (78%
overall primary patency, 95% prevention of major
amputation in CLI patients) in a variety of lesions, in
patients with and without diabetes, and in claudicantsand CLI patients (4). Additionally, the EXCITE ISR
(EXCImer Laser Randomized Controlled Study for
Treatment of FemoropopliTEal In-Stent Restenosis)
trial demonstrated a signiﬁcant reduction in TLR that
favored laser atherectomy over PTA for femo-
ropopliteal ISR in a randomized, controlled trial with
long lesions (5). The ongoing large LIBERTY 360 trial is
attempting to demonstrate real-world comparative
outcomes for multiple atherectomy, PTA, and stent
modalities in diverse lesion subsets involving the
popliteal and infrapopliteal arteries.
Devices and techniques for revascularization have
evolved rapidly since 2006. Several different athe-
rectomy devices, including directional, orbital, rota-
tional, excisional, and laser atherectomy devices,
have been approved in the United States since 1998.
However, some devices only gained signiﬁcant
adoption in recent years due to technological evolu-
tion, clinical evidence, and improved understanding
of endovascular techniques. Of note, the article sug-
gests that improved outpatient reimbursement led to
growth in use of atherectomy in the outpatient
setting (1); in fact, inpatient atherectomy procedures
increased 30.3% from 2010 to 2011 (see Table 3 in
Jones et al. [1]), whereas outpatient atherectomy
increased by 20.4%, potentially indicating that other
(nonﬁnancial) factors may have inﬂuenced the in-
crease in atherectomy use. Although signiﬁcant
challenges exist in designing and funding random-
ized comparative effectiveness trials for all patient
and lesion subsets, we continue to gain new infor-
mation regarding performance and durability of
procedures.
Although there are economic drivers that dictate
care in all locations of service, outliers exist in every
specialty and site of service. It is believed that most
physicians strive to do what is in the best interest of
their patients. There is concern with singling out a
speciﬁc therapy from a retrospective dataset without
consideration of all the inherent episodic costs,
especially when excluding data representing probable
signiﬁcant savings to Medicare by reduction in more
costly inpatient surgical services. In the interests of
the patients who present with this challenging dis-
ease state, the interventionalists who are thought-
fully trying to care for them, and the payers, such as
Centers for Medicare and Medicaid Services, who are
interested in reducing overall costs, additional
ﬁnancial analyses and assessments of true costs are
critical for accurate and informed decision making.
Only then can conclusions be made about value for
speciﬁc therapies to treat PAD in each site of service,
with the overall aim of improving patient access to
quality care.
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Coll Cardiol 2015;8:92–101.REPLY: Era of Change in Sites of Service for
Peripheral Vascular Intervention Requires
New Ways to Look at CostsWe appreciate the opportunity to respond to a letter
written by Dr. Carr regarding our article published in
the Journal in March 2015 (1). We believe our
methods, results, and interpretation were a balanced,
descriptive report of current trends and the landscape
of peripheral vascular intervention (PVI) in the
U.S. Medicare population. Our main ﬁndings include:
1) a stabilization in the rate of PVIs in the United
States and a shift in care location from inpatient
settings to outpatient settings and ofﬁce-based
clinics; 2) increasing numbers of atherectomy pro-
cedures, which are associated with higher Medicare
expenditures than angioplasty and stenting pro-
cedures; and 3) the likelihood of neutralization of
cost savings for Medicare due to more expensive
procedures.
We would like to address Dr. Carr’s points of
clariﬁcation directly. First, our primary intent in
highlighting the increase in atherectomy procedures
in ofﬁce-based clinics was actually due to the fact
that changes to the Outpatient Prospective Payment
System (OPPS) occurred in 2008 and that theseprocedures were reimbursed by Medicare after that
time, a point seemingly similar to that stated by
Dr. Carr. Our further emphasis on the increase in
atherectomy was based on the increased costs to
Medicare and the limited evidence supporting its
use, therefore we think that this focus was
warranted.
Second, mean costs in our analysis were derived
from the sum of expenditures by Medicare and by
Medicare beneﬁciaries. These data were thoroughly
investigated, and in the online supplement, these
costs were reported separately for atherectomy alone
and for atherectomy plus stenting. We believe our
conclusions that atherectomy procedures were asso-
ciated with higher costs to Medicare and to Medicare
beneﬁciaries than those with stenting or angioplasty
procedures are ﬁrm.
Third, our analysis purposefully eliminated surgi-
cal revascularization procedures as there had been a
well-documented reduction in surgical revasculari-
zation over the past 2 decades, an occurrence that
pre-dated the changes to the OPPS (2,3). Our primary
intent was to evaluate the impact of changes in
OPPS, and because endovascular revascularization
was more commonly performed in outpatient settings
(and surgical revascularization was infrequently per-
formed in outpatient settings), we thought that the
impact of the changes in OPPS on the trends and costs
of endovascular revascularization would be more
apparent.
Fourth, although we agree that patients in our
study who received atherectomy appear to be
sicker than those patients undergoing angioplasty
or stenting, there is no evidence that atherectomy
is more effective for patients with critical limb
ischemia, as Dr. Carr states. We also disagree with
Dr. Carr that “differences in patient populations
could also indicate an improved access to care
(i.e., patients were treated who would otherwise
have been treated surgically or who would not
have undergone revascularization at all).” In fact,
these data are limited by an inability to evaluate
whether access to care was affected by the changes
in OPPS.
Fifth, we highlighted the paucity of data support-
ing use of atherectomy because we think that more
studies are needed in PAD patients to guide decision
making. We also do not think that Dr. Carr’s state-
ment that “[D]ata clearly demonstrate that PTA alone
in the femoropopliteal artery segment is not a satis-
factory procedure” should prompt clinicians to use
atherectomy more. Like all complex decision making,
multiple factors likely contribute to the ﬁndings in
our study, including patient-speciﬁc factors and
